Education
About Us
Working with TipRanks
Follow Us
Vistagen Therapeutics Inc. (VTGN)
:VTGN
Total Valuation
VistaGen Therapeutics has a market cap or net worth of $150.08M. The enterprise value is $51.60M.
Market Cap$150.08M
Enterprise Value$51.60M
Share Statistics
VistaGen Therapeutics has 39,495,453 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding39,495,453
Owned by Insiders0.46%
Owned by Institutions1.46%
Financial Efficiency
VistaGen Therapeutics’s return on equity (ROE) is -0.73 and return on invested capital (ROIC) is -77.44%.
Return on Equity (ROE)-0.73
Return on Assets (ROA)-0.61
Return on Invested Capital (ROIC)-77.44%
Return on Capital Employed (ROCE)-0.78
Revenue Per Employee10.13K
Profits Per Employee-1.07M
Employee Count48
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of VistaGen Therapeutics is ―. VistaGen Therapeutics’s PEG ratio is -0.15.
PE Ratio―
PS Ratio157.98
PB Ratio1.09
Price to Fair Value1.09
Price to FCF-1.82
Price to Operating Cash Flow-3.13
PEG Ratio-0.15
Income Statement
In the last 12 months, VistaGen Therapeutics had revenue of 486.00K and earned -51.42M in profits. Earnings per share was -1.67.
Revenue486.00K
Gross Profit486.00K
Operating Income-55.97M
Pretax Income-51.41M
Net Income-51.42M
EBITDA-55.34M
Earnings Per Share (EPS)-1.67
Cash Flow
In the last 12 months, operating cash flow was -52.95M and capital expenditures -148.00K, giving a free cash flow of -53.09M billion.
Operating Cash Flow-52.95M
Free Cash Flow-53.09M
Free Cash Flow per Share-1.34
Dividends & Yields
VistaGen Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.87
52-Week Price Change81.54%
50-Day Moving Average3.90
200-Day Moving Average2.93
Relative Strength Index (RSI)64.68
Average Volume (3m)515.46K
Important Dates
VistaGen Therapeutics upcoming earnings date is Feb 12, 2026, TBA (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateFeb 12, 2026
Ex-Dividend Date―
Financial Position
VistaGen Therapeutics as a current ratio of 6.51, with Debt / Equity ratio of 1.82%
Current Ratio6.51
Quick Ratio6.51
Debt to Market Cap0.00
Net Debt to EBITDA1.19
Interest Coverage Ratio0.00
Taxes
In the past 12 months, VistaGen Therapeutics has paid 7.00K in taxes.
Income Tax7.00K
Effective Tax Rate>-0.01
Enterprise Valuation
VistaGen Therapeutics EV to EBITDA ratio is -0.20, with an EV/FCF ratio of -0.26.
EV to Sales22.96
EV to EBITDA-0.20
EV to Free Cash Flow-0.26
EV to Operating Cash Flow-0.27
Balance Sheet
VistaGen Therapeutics has $77.17M in cash and marketable securities with $1.86M in debt, giving a net cash position of $75.31M billion.
Cash & Marketable Securities$77.17M
Total Debt$1.86M
Net Cash$75.31M
Net Cash Per Share$1.91
Tangible Book Value Per Share$2.29
Margins
Gross margin is 40.78%, with operating margin of -11517.08%, and net profit margin of -10579.84%.
Gross Margin40.78%
Operating Margin-11517.08%
Pretax Margin-10578.40%
Net Profit Margin-10579.84%
EBITDA Margin-11386.42%
EBIT Margin-11517.08%
Analyst Forecast
The average price target for VistaGen Therapeutics is $15.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$15.50
Price Target Upside288.47% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-33.00%
EPS Growth Forecast54.91%